{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:37:21Z","timestamp":1787020641439,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Horizon Pharma USA, Inc.","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12969-018-0260-y","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T20:23:54Z","timestamp":1529958234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A 6-month, multicenter, open-label study of fixed dose naproxen\/esomeprazole in adolescent patients with juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"16","author":[{"given":"Daniel J.","family":"Lovell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Dare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Francis-Sedlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Von Scheven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Jerath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oral","family":"Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zeft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Naddaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-2273","authenticated-orcid":false,"given":"Robert J.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"issue":"2","key":"260_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"2","key":"260_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s12016-014-8460-9","volume":"49","author":"D Rigante","year":"2015","unstructured":"Rigante D, Bosco A, Esposito S. The etiology of juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2015;49(2):253\u201361.","journal-title":"Clin Rev Allergy Immunol"},{"key":"260_CR3","doi-asserted-by":"crossref","unstructured":"Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013;65(10):2499\u20132512.","DOI":"10.1002\/art.38092"},{"issue":"4","key":"260_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis care Res. 2011;63(4):465\u201382.","journal-title":"Arthritis care Res"},{"issue":"1","key":"260_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12969-017-0219-4","volume":"16","author":"A Sura","year":"2018","unstructured":"Sura A, Failing C, Sturza J, Stannard J, Riebschleger M. Patient characteristics associated with response to NSAID monotherapy in children with systemic juvenile idiopathic arthritis. Pediatr Rheumatol. 2018;16(1):2.","journal-title":"Pediatr Rheumatol"},{"issue":"10","key":"260_CR6","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.autrev.2017.07.014","volume":"16","author":"R Cimaz","year":"2017","unstructured":"Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: a state of the art review. Autoimmun Rev. 2017;16(10):1008\u201315.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"260_CR7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3899\/jrheum.080073","volume":"36","author":"I Foeldvari","year":"2009","unstructured":"Foeldvari I, Szer IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, et al. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol. 2009;36(1):174\u201382.","journal-title":"J Rheumatol"},{"key":"260_CR8","unstructured":"Nexium [package insert]. AstraZeneca pharmaceuticals LP, Wilmington; 2016."},{"issue":"5","key":"260_CR9","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1542\/peds.2006-0421","volume":"117","author":"J Cassidy","year":"2006","unstructured":"Cassidy J, Kivlin J, Lindsley C, Nocton J. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006;117(5):1843\u20135.","journal-title":"Pediatrics"},{"key":"260_CR10","doi-asserted-by":"crossref","unstructured":"Cassidy J, Petty R, Laxer R, Lindsley C. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Elsevier; 2011.","DOI":"10.1016\/B978-1-4160-6581-4.10002-0"},{"issue":"2","key":"260_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.pcl.2005.01.007","volume":"52","author":"JE Weiss","year":"2005","unstructured":"Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Pediatr Clin N Am. 2005;52(2):413\u201342. vi","journal-title":"Pediatr Clin N Am"},{"issue":"2 Suppl 4th Rep","key":"260_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1542\/peds.114.2.S2.555","volume":"114","author":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents","year":"2004","unstructured":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555\u201376.","journal-title":"Pediatrics"},{"issue":"7","key":"260_CR13","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3899\/jrheum.091474","volume":"37","author":"G Filocamo","year":"2010","unstructured":"Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010;37(7):1534\u201341.","journal-title":"J Rheumatol"},{"issue":"12","key":"260_CR14","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.1780371209","volume":"37","author":"G Singh","year":"1994","unstructured":"Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37(12):1761\u20139.","journal-title":"Arthritis Rheum"},{"key":"260_CR15","unstructured":"VIMOVO NDA 22511 Efficacy Supplement 2017. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM571347.pdf\n                    \n                  . Accessed 21 Jan 2018."},{"issue":"9\u201310","key":"260_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s002280000206","volume":"56","author":"M Hassan-Alin","year":"2000","unstructured":"Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol. 2000;56(9\u201310):665\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"260_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.clinthera.2006.03.010","volume":"28","author":"J Li","year":"2006","unstructured":"Li J, Zhao J, Hamer-Maansson JE, Andersson T, Fulmer R, Illueca M, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther. 2006;28(3):419\u201327.","journal-title":"Clin Ther"},{"issue":"10","key":"260_CR18","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1177\/0091270011418658","volume":"52","author":"P Valitalo","year":"2012","unstructured":"Valitalo P, Kumpulainen E, Manner M, Kokki M, Lehtonen M, Hooker AC, et al. Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children. J Clin Pharmacol. 2012;52(10):1516\u201326.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"260_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/j.1552-4604.1994.tb03962.x","volume":"34","author":"TG Wells","year":"1994","unstructured":"Wells TG, Mortensen ME, Dietrich A, Walson PD, Blasier D, Kearns GL. Comparison of the pharmacokinetics of naproxen tablets and suspension in children. J Clin Pharmacol. 1994;34(1):30\u20133.","journal-title":"J Clin Pharmacol"},{"key":"260_CR20","unstructured":"Naprosyn [package insert]. Genentech, San Francisco; 2013."},{"issue":"12","key":"260_CR21","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","volume":"98","author":"P Miner Jr","year":"2003","unstructured":"Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616\u201320.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"260_CR22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1572-0241.2006.00499.x","volume":"101","author":"JM Scheiman","year":"2006","unstructured":"Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101(4):701\u201310.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"260_CR23","first-page":"2036","volume":"26","author":"RQ Cron","year":"1999","unstructured":"Cron RQ, Sharma S, Sherry DD. Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol. 1999;26(9):2036\u20138.","journal-title":"J Rheumatol"},{"issue":"5","key":"260_CR24","first-page":"985","volume":"33","author":"A Reiff","year":"2006","unstructured":"Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, Goodman S, Zavaler MF, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006;33(5):985\u201395.","journal-title":"J Rheumatol"},{"issue":"5","key":"260_CR25","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0031-3955(16)40055-6","volume":"42","author":"EH Giannini","year":"1995","unstructured":"Giannini EH, Cawkwell GD. Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Pediatr Clin N Am. 1995;42(5):1099\u2013125.","journal-title":"Pediatr Clin N Am"},{"key":"260_CR26","unstructured":"Vimovo [package insert]. Horizon Pharma USA, Inc., Lake Forest; 2017."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0260-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-018-0260-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0260-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T19:10:23Z","timestamp":1561489823000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-018-0260-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["260"],"URL":"https:\/\/doi.org\/10.1186\/s12969-018-0260-y","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"29 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An Institutional Review Board (IRB)\/Ethics Committee (EC) from each clinical study site approved the final study protocol, and the final version of the informed consent form and assent form and any other written information and\/or materials provided to the patients before any patients were entered in the study. Before being implemented, protocol amendments were reviewed and approved by the IRBs.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.J.L. receives grant \/ research support from the National Institutes of Health, NIAMS; Cincinnati Children\u2019s Hospital Medical Center receives funds for DJL consulting from AstraZeneca, Bristol-Myers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Forest Research Institute, Horizon, Johnson & Johnson, Biogen, Takeda, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Celgene, and Janssen for consulting; He is on the speaker bureaus of Genentech and Bristol Meyers Squibb. J.A.D. has received research support from AbbVie, AstraZeneca, Bristol-Myers Squibb, Horizon Pharma, Medac, Pfizer, Roche and UCB. D.G. is on Novartis speaker bureau. L.J. has received research support from Abbvie, GSk, Hoffman-Laroche, Pfizer and UCB. A.Z. has stock ownership in Merck and OPKO. J.B., B.D.L., M. F. and R.J. H. are employees of, and have stock in, Horizon Pharma USA, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"41"}}